Chemical formula: C₁₀H₁₇N Molecular mass: 151.249 g/mol PubChem compound: 2130
Amantadine has been shown to be a low affinity antagonist at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. Overactivity of glutamatergic neurotransmission has been implicated in the generation of parkinsonian symptoms. In addition, amantadine specifically inhibits the replication of influenza A viruses at low concentrations.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N04BB01 | Amantadine | N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BB Adamantane derivatives |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| TRILASYM Oral solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Amantadine is an active ingredient of these brands:
United States (US)Albania (AL)
Australia (AU)
Austria (AT)
Brazil (BR)
Croatia (HR)
Estonia (EE)
France (FR)
Hong Kong (HK)Israel (IL)
Japan (JP)
Lithuania (LT)
Mexico (MX)
Netherlands (NL)
New Zealand (NZ)
Romania (RO)
Singapore (SG)
Tunisia (TN)Turkey (TR)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
